Peripheral nerve stimulators are medical devices designed to deliver electrical impulses to peripheral nerves for therapeutic purposes. These devices are often used to manage chronic pain, especially when other treatments have not been successful.
Latest Peripheral Nerve Stimulators Companies Update
Nov 2023: The US Food and Drug Administration (FDA) has approved Medtronic's Symplicity Spyralrenal Denervation (RDN) device for treating hypertension. With this permission, the company may start selling the RDN system—also called the Symplicity blood pressure procedure—immediately. The goal of the minimally invasive procedure is to apply radiofrequency radiation to the kidney-neighbor nerves, which can become hyperactive and cause elevated blood pressure. Once the patient is sedated, the physician inserts a solitary, thin tube into the kidney's artery. Once the tube is inserted, the physician stimulates the system to reduce hyperactivity in the kidney-related nerves. Although the RDN system is now only available for experimental use in Japan, China, and Canada, it has gained commercial approval in over 70 countries globally.
Peripheral Nerve Stimulators Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)